NCT01760525View on ClinicalTrials.gov

A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 20, 2013

Primary Completion Date

July 24, 2020

Study Completion Date

July 24, 2020

Conditions
Solid Tumor With p53 Wild Type Status
Interventions
DRUG

CGM097

Patients treated with CGM097

Trial Locations (5)

8091

Novartis Investigative Site, Zurich

45147

Novartis Investigative Site, Essen

69373

Novartis Investigative Site, Lyon

169610

Novartis Investigative Site, Singapore

02215

Dana Farber Cancer Institute SC (2), Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY